Welcome to BioMarket Group!

Analytical Tool - Leukemia

Additional Information

Published Date Mar 25, 2014
Pages No
License Prices No
PDF Fact Sheet No
Format PDF & Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group

Availability: In stock

$4,650.00

Quick Overview

A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics.
Request free sample pages from Analytical Tool - Leukemia

"Analytical Tool - Leukemia" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers - A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
and Leukemia Drug Pipeline Update 2014*
.


The Package Includes:

  • A progress analysis on current and emerging drugs
  • Information on most companies active in leukemia R&D
  • Information on key industry related leukemia projects
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs


This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of leukemia therapeutics
  • Identifying emerging leukemia products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of leukemia drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.



License Prices:

Request free sample pages from Analytical Tool - Leukemia

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Prostate Cancer
A unique tool for analyzing the complex competitive pressure within the field of prostate cancer. Learn More


Analytical Tool - Apoptosis in Oncology
In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic mechanism. Learn More

Other selected research from the 'R&D' category:


IL-5 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More


EGFR1 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 554 companies plus partners who are today developing 852 EGFR1 pathway targeting drugs in 3067 developmental projects in cancer across 295 different targets. In addition, there are 5 suspended drugs and another 379 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Analytical Tool - Angiogenesis in Oncology
The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More


Analytical Tool - Hematological Cancers
"Analytical Tool Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. Learn More